Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Merck
Chubb
Harvard Business School
Daiichi Sankyo
Teva
US Army
Deloitte

Generated: October 19, 2017

DrugPatentWatch Database Preview

ZEPATIER Drug Profile

« Back to Dashboard

Which patents cover Zepatier, and when can generic versions of Zepatier launch?

Zepatier is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has ninety-two patent family members in thirty-nine countries and eleven supplementary protection certificates in five countries.

The generic ingredient in ZEPATIER is elbasvir; grazoprevir. One supplier is listed for this compound. Additional details are available on the elbasvir; grazoprevir profile page.

Summary for Tradename: ZEPATIER

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list14
Drug Prices:see details
DailyMed Link:ZEPATIER at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZEPATIER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,654Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors► Subscribe
9,090,661Inhibitors of hepatitis C virus replication► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZEPATIER

Country Document Number Estimated Expiration
Honduras2011000209► Subscribe
Morocco32502► Subscribe
Hong Kong1173402► Subscribe
Japan2011528713► Subscribe
Cyprus1115503► Subscribe
Serbia52534► Subscribe
China102427729► Subscribe
EcuadorSP11010777► Subscribe
Australia2009274190► Subscribe
Denmark2410844► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZEPATIER

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016049Lithuania► SubscribePRODUCT NAME: GRAZOPREVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
0160050Estonia► Subscribe(93) SZ 65861 01, 01.04.2016 (93) CH 65861 01, 01.04.2016
2016 00069Denmark► SubscribePRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
0858Netherlands► SubscribePRODUCT NAME: ELBASVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1119 20160726
2016 00070Denmark► SubscribePRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
0160050 00207Estonia► SubscribePRODUCT NAME: ELBASVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016
2016048Lithuania► SubscribePRODUCT NAME: ELBASVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
2017000002Germany► SubscribePRODUCT NAME: GRAZOPREVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON.; REGISTRATION NO/DATE: EU/1/16/1119 20160722
0160051 00215Estonia► SubscribePRODUCT NAME: GRASOPREVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016
2017000001Germany► SubscribePRODUCT NAME: ELBASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1119 20160722
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Merck
US Department of Justice
Mallinckrodt
Accenture
Cipla
Queensland Health
Daiichi Sankyo
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot